Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) Other Non Operating Income (2017 - 2020)

Outlook Therapeutics (OTLK) has disclosed Other Non Operating Income for 3 consecutive years, with $6.2 million as the latest value for Q2 2020.

  • Quarterly Other Non Operating Income rose 1554.92% to $6.2 million in Q2 2020 from the year-ago period, while the trailing twelve-month figure was -$1.9 million through Jun 2020, down 212.28% year-over-year, with the annual reading at -$577659.0 for FY2023, 43.67% up from the prior year.
  • Other Non Operating Income for Q2 2020 was $6.2 million at Outlook Therapeutics, up from -$8.1 million in the prior quarter.
  • The five-year high for Other Non Operating Income was $6.2 million in Q2 2020, with the low at -$8.1 million in Q4 2019.
  • Average Other Non Operating Income over 3 years is -$751177.8, with a median of -$423686.0 recorded in 2019.
  • Peak annual rise in Other Non Operating Income hit 1554.92% in 2020, while the deepest fall reached 1554.92% in 2020.
  • Over 3 years, Other Non Operating Income stood at -$1.3 million in 2017, then tumbled by 543.63% to -$8.1 million in 2019, then soared by 176.47% to $6.2 million in 2020.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at $6.2 million, -$8.1 million, and -$423686.0 for Q2 2020, Q4 2019, and Q2 2019 respectively.